We found the expression of at least one of the 46 genes was detected in all but one Her2-positive patient, whereas the traditional detection of DTCs by ICC methods averages 20–30% in similarly staged breast cancer patients [5, 6]. This evidence concerns the gene ERBB2 and breast carcinoma.